

PHARMACY POLICY STATEMENT

Ohio Medicaid

DRUG NAME	Kalydeco (ivacaftor)
BILLING CODE	Must use valid NDC code
BENEFIT TYPE	Pharmacy
SITE OF SERVICE ALLOWED	Home
COVERAGE REQUIREMENTS	Prior Authorization Required (Preferred Product) QUANTITY LIMIT— 150 mg tablets - 60 per 30 days 50 mg & 75 mg granules - 56 per 30 days
LIST OF DIAGNOSES CONSIDERED NOT MEDICALLY NECESSARY	Click Here

Kalydeco (ivacaftor) is a **preferred** product and will only be considered for coverage under the **pharmacy** benefit when the following criteria are met:

Members must be clinically diagnosed with one of the following disease states and meet their individual criteria as stated.

CYSTIC FIBROSIS

For **initial** authorization:

1. Member must be 12 months of age or older; AND
2. Medication must be prescribed by a pulmonologist or an infectious disease specialist; AND
3. Member has had genetic testing documented in chart notes with one of the following mutations in the CFTR gene: 2789+5G→A, 3272-26A→G, 3849+10kbC→T, 711+3A→G, A1067T, A455E, D110E, D110H, D1152H, D1270N, D579G, E193K, E56K, E831X, F1052V, F1074L, G1069R, G1244E, G1349D, G178R, G551D, G551S, K1060T, L206W, P67L, R1070Q, R1070W, R117C, R117H, R347H, R352Q, R74W, S1251N, S1255P, S549N, S549R, S945L, or S977F.
4. **Dosage allowed:** Up to 150 mg every 12 hours. See package insert for details on dosing.

If member meets all the requirements listed above, the medication will be approved for 3 months.

For **reauthorization**:

1. Member must be in compliance with all other initial criteria; AND
2. Member's adherence to medication is confirmed by claims history.

If member meets all the reauthorization requirements above, the medication will be approved for an additional 12 months.

CareSource considers Kalydeco (ivacaftor) not medically necessary for the treatment of the diseases that are not listed in this document.

DATE	ACTION/DESCRIPTION
06/12/2017	New policy for Kalydeco created.
10/05/2018	New CFTD gene mutations added. Age coverage expanded (approved for 12 months old members and older).

References:

1. Kalydeco [package insert]. Boston, MA: Vertex Pharmaceuticals Inc; August, 2018.
2. Kalydeco. Micromedex Solutions. Truven Health Analytics, Inc. Ann Arbor, MI. Available at: <http://www.micromedexsolutions.com>. Accessed March 6, 2017.

3. National Guideline Clearinghouse (NGC). Guideline summary: Cystic fibrosis pulmonary guidelines. Chronic medications for maintenance of lung health. In: National Guideline Clearinghouse (NGC) [Web site]. Rockville (MD): Agency for Healthcare Research and Quality (AHRQ); 2013 Apr 01. Available: <https://www.atsjournals.org/doi/full/10.1164/rccm.201207-1160OE>. Accessed November 27, 2018.

Effective date: 12/13/2018

Revised date: 10/05/2018